Fig. 1From: Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA studyPatient disposition. *Of 123 patients, 104 completed the longitudinal phase and 19 discontinued, 8 of whom were lost to follow-up, 7 patients voluntarily discontinued the study and 4 patients withdrew for to other reasons. (SAA, severe allergic asthma)Back to article page